Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
MannKind (Nasdaq: MNKD) has announced significant changes to its Board of Directors. Kent Kresa, who has served on the board since June 2004 and was Chairman from 2016 to 2020, will retire effective September 30, 2024. He will continue as Chairman Emeritus. Steven B. Binder, the company's former Chief Financial Officer, will join the board on the same date.
Binder, who served as CFO from July 2017 to April 2024, is currently Executive Vice President of Special Projects. He will step down from this role when he joins the board. James S. Shannon, current Chairman, praised Kresa's two decades of leadership and expressed enthusiasm for Binder's appointment, citing his financial stewardship and role in diversifying MannKind's revenue streams. The board will maintain nine members following these changes.
MannKind (Nasdaq: MNKD) ha annunciato cambiamenti significativi nel suo Consiglio di Amministrazione. Kent Kresa, che è stato membro del consiglio da giugno 2004 e Presidente dal 2016 al 2020, si ritirerà il 30 settembre 2024. Continuerà a svolgere il ruolo di Presidente Emerito. Steven B. Binder, ex Direttore Finanziario dell'azienda, entrerà nel consiglio nella stessa data.
Binder, che ha ricoperto il ruolo di CFO da luglio 2017 ad aprile 2024, è attualmente Vice Presidente Esecutivo per Progetti Speciali. Si dimetterà da questo incarico quando entrerà nel consiglio. James S. Shannon, attuale Presidente, ha elogiato i due decenni di leadership di Kresa ed ha espresso entusiasmo per la nomina di Binder, sottolineando la sua gestione finanziaria e il ruolo nella diversificazione dei flussi di entrate di MannKind. Il consiglio manterrà nove membri dopo questi cambiamenti.
MannKind (Nasdaq: MNKD) ha anunciado cambios significativos en su Junta Directiva. Kent Kresa, quien ha sido miembro de la junta desde junio de 2004 y Presidente desde 2016 hasta 2020, se retirará el 30 de septiembre de 2024. Continuará como Presidente Emérito. Steven B. Binder, ex Director Financiero de la empresa, se unirá a la junta en la misma fecha.
Binder, quien fue CFO de julio de 2017 a abril de 2024, es actualmente Vicepresidente Ejecutivo de Proyectos Especiales. Dejará su cargo cuando se una a la junta. James S. Shannon, actual Presidente, elogió los dos décadas de liderazgo de Kresa y expresó entusiasmo por la nombramiento de Binder, citando su gestión financiera y su papel en la diversificación de los flujos de ingresos de MannKind. La junta mantendrá nueve miembros después de estos cambios.
MannKind (Nasdaq: MNKD)는 이사회에 중요한 변화가 있음을 발표했습니다. Kent Kresa는 2004년 6월부터 이사로 활동해왔으며, 2016년부터 2020년까지 의장을 맡았고, 2024년 9월 30일부로 은퇴하게 됩니다. 그는 명예 의장직을 이어갈 것입니다. Steven B. Binder, 전 회사 재무 담당 최고 책임자가 같은 날 이사회에 합류합니다.
Binder는 2017년 7월부터 2024년 4월까지 CFO로 재직했으며, 현재 특별 프로젝트 부회장입니다. 그는 이사회에 합류할 때 이직합니다. 현 의장인 James S. Shannon은 Kresa의 20년간의 리더십을 찬양하며, Binder의 임명에 대한 기대감을 표명하였고, 그의 재정 관리 및 MannKind의 수익원 다각화에 기여한 점을 언급했습니다. 이사회는 이러한 변화 이후 아홉 명의 이사로 유지됩니다.
MannKind (Nasdaq: MNKD) a annoncé des changements significatifs au sein de son Conseil d'Administration. Kent Kresa, qui siège au conseil depuis juin 2004 et a été Président de 2016 à 2020, prendra sa retraite le 30 septembre 2024. Il continuera en tant que Président Émérite. Steven B. Binder, l'ancien Directeur Financier de l'entreprise, rejoindra le conseil à la même date.
Binder, qui a été CFO de juillet 2017 à avril 2024, est actuellement Vice-Président Exécutif des Projets Spéciaux. Il quittera ce rôle lorsqu'il rejoindra le conseil. James S. Shannon, Président actuel, a salué les deux décennies de leadership de Kresa et a exprimé son enthousiasme pour la nomination de Binder, citant sa gestion financière et son rôle dans la diversification des sources de revenus de MannKind. Le conseil comptera neuf membres après ces changements.
MannKind (Nasdaq: MNKD) hat bedeutende Veränderungen im Vorstand bekannt gegeben. Kent Kresa, der seit Juni 2004 im Vorstand ist und von 2016 bis 2020 den Vorsitz führte, wird zum 30. September 2024 zurücktreten. Er wird als Vorsitzender Emeritus weiterhin tätig sein. Steven B. Binder, der ehemalige Chief Financial Officer des Unternehmens, wird am selben Tag dem Vorstand beitreten.
Binder, der von Juli 2017 bis April 2024 CFO war, ist derzeit Executive Vice President für Sonderprojekte. Er wird von diesem Posten zurücktreten, wenn er dem Vorstand beitritt. James S. Shannon, der derzeitige Vorsitzende, lobte Kresas zwei Jahrzehnte an Führung und äußerte sich begeistert über Binders Ernennung, indem er auf dessen finanzielle Kompetenz und Rolle bei der Diversifizierung der Einnahmequellen von MannKind hinwies. Der Vorstand wird nach diesen Änderungen weiterhin aus neun Mitgliedern bestehen.
- Appointment of former CFO Steven B. Binder to the Board, bringing financial expertise
- Maintaining board size at nine members, ensuring continuity in governance
- Retention of Kent Kresa's experience through Chairman Emeritus role
- Loss of long-standing board member Kent Kresa's active involvement
- Transition period as new board member adapts to role
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Kent Kresa has decided to retire from MannKind’s Board of Directors effective September 30, 2024. In addition, the Board of Directors has appointed Steven B. Binder to the Board, also effective September 30, 2024.
Kresa, who has served on MannKind’s Board of Directors since June 2004, was Chairman from 2016 until December 2020. Upon his retirement from the MannKind Board, Mr. Kresa will continue to be associated with the company in the capacity of Chairman Emeritus.
Binder previously served as MannKind’s Chief Financial Officer from July 2017 until April 2024 and currently serves as Executive Vice President, Special Projects. Mr. Binder will remain in that role until he joins the Board of Directors on September 30, 2024, after which he will no longer be an employee of the Company.
“We are sincerely grateful for two decades of invaluable leadership that Kent has provided the Board of Directors,” said James S. Shannon, Chairman of the Board. “We are looking forward to Steve joining the Board as he was instrumental in providing financial stewardship to MannKind during his tenure and helped bring MannKind into its current era with multiple revenue streams and healthy pipeline progression.”
With the addition of Binder, there will remain nine total members of the MannKind Board of Directors.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
MANNKIND is a registered trademark of MannKind Corporation.
FAQ
When will Kent Kresa retire from MannKind's (MNKD) Board of Directors?
Who will replace Kent Kresa on MannKind's (MNKD) Board of Directors?
What role will Kent Kresa have with MannKind (MNKD) after his retirement from the Board?
What was Steven B. Binder's previous role at MannKind (MNKD)?
